|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2007-1-1
|
|
pubmed:abstractText |
Alemtuzumab (Campath-1H) induction with tacrolimus monotherapy has been shown to provide effective immunosuppression for kidney, liver, lung, and small bowel transplantation. This drug combination was evaluated in pancreas transplant recipients.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
82
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1621-4
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17198247-Antibodies, Monoclonal,
pubmed-meshheading:17198247-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17198247-Antibodies, Neoplasm,
pubmed-meshheading:17198247-Drug Therapy, Combination,
pubmed-meshheading:17198247-Graft Rejection,
pubmed-meshheading:17198247-Graft Survival,
pubmed-meshheading:17198247-Humans,
pubmed-meshheading:17198247-Immunosuppression,
pubmed-meshheading:17198247-Immunosuppressive Agents,
pubmed-meshheading:17198247-Pancreas Transplantation,
pubmed-meshheading:17198247-Tacrolimus,
pubmed-meshheading:17198247-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.
|
|
pubmed:affiliation |
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA 15213, USA. thainl@upmc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|
